Company · TAK
Takeda
Last checked: Nov 19, 2026Source: Drugs@FDA, ClinicalTrials.gov
NDAs and BLAs
63
40 still marketed
Novel approvals
33
Approvals since 2021
22
Originals and new uses
Phase 3 trials
545
Registered, any status
Trials by phase
All registered drug and biologic trials with this lead sponsor, any status. A public view of the pipeline.
Recent approvals
Originals and efficacy supplements, newest first.
- Mimrylo approved NovelPriority reviewOrphanAug 28, 2026
- Orzeyful approved NovelPriority reviewOrphanAug 5, 2026
- Livtencity new use OrphanNov 21, 2025
- Iclusig new use OrphanOct 10, 2025
- Motegrity new use Jul 10, 2025
- Entyvio approved Apr 18, 2024
- Iclusig new use Priority reviewOrphanMar 19, 2024
- Eohilia approved Breakthrough therapyPriority reviewOrphanFeb 9, 2024
- Fruzaqla approved NovelPriority reviewNov 8, 2023
- Entyvio approved Sep 27, 2023
Drugs in development (18)
Investigational drugs, not yet FDA-approved, in this company's active or recent Phase 2 and 3 trials. Phase 3 first.
- ZasocitinibTAK- 279, NDI-034858Phase 317 trials
Takeda · Plaque Psoriasis, Psoriatic Arthritis, Crohn's Disease
- ElriterceptTAK-226, KER-050Phase 36 trials
Takeda · Myelodysplastic Syndromes, Myelofibrosis, Anemia
- TDVTAK-003, Tetravalent Dengue VaccinePhase 35 trials
Takeda · Dengue Fever, Healthy Volunteers
- MezagitamabTAK-079Phase 34 trials
Takeda · Immune Thrombocytopenic Purpura (ITP), Antibody-Mediated Rejection (AMR), Kidney Disease
- TAK-360Phase 34 trials
Takeda · Narcolepsy Type 1, Idiopathic Hypersomnia, Narcolepsy Type 2
- FazirsiranTAK-999, ARO-AATPhase 33 trials
Takeda · Alpha1-Antitrypsin Deficiency
- TAK-755rADAMTS13, recombinant ADAMTS13Phase 33 trials
Takeda · Thrombotic Thrombocytopenic Purpura (TTP), Acute Ischemic Stroke
- TAK-771Phase 32 trials
Takeda · Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP), Multifocal Motor Neuropathy (MMN), Primary Immunodeficiency Diseases (PID)
- TAK-330Phase 31 trial
Takeda · Coagulation Disorder
- TAK-928Phase 31 trial
Takeda · IO Resistant Squamous and Nonsquamous NSCLC
- AskBio009BAX 335Phase 21 trial
Takeda · Hemophilia B
- HGT-1110Recombinant human arylsulfatase APhase 21 trial
Takeda · Metachromatic Leukodystrophy (MLD)
- TAK-007Phase 21 trial
Takeda · Relapsed or Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL)
- TAK-101Phase 21 trial
Takeda · Celiac Disease
- TAK-188Phase 21 trial
Takeda · Advanced or Metastatic Solid Tumors
- TAK-341MEDI1341Phase 21 trial
Takeda · Multiple System Atrophy
- TAK-411Hypersialylated Immune Globulin GPhase 21 trial
Takeda · Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)
- TAK-505Phase 21 trial
Takeda · Malignant Solid Tumors
Recruiting Phase 3 trials
Largest first.
- A Study Comparing TAK-928 With Docetaxel in Adults With Non-Small Cell Lung CancerPivotal-lookingRecruiting
TakedaTakeda (TAK)
NCT07217301 · 1,200 participants (planned) · Start Nov 26, 2025 · Primary completion Nov 1, 2028
Drug: TAK-928; Control Arm · For: IO Resistant Squamous and Nonsquamous NSCLC
Sites: Jonesboro, Arkansas; Fair Oaks, California; Fountain Valley, California · 50 sites in all
- Continuation Study of Zasocitinib in Adults With Psoriatic ArthritisPivotal-lookingRecruiting
TakedaTakeda (TAK)
NCT07286058 · 1,182 participants (planned) · Start Mar 11, 2026 · Primary completion Dec 18, 2029
Drug: Zasocitinib · For: Psoriatic Arthritis
Sites: Tucson, Arizona; Fountain Valley, California; La Mesa, California · 111 sites in all
- A Study of TAK-861 for the Treatment of Selected Central Hypersomnia ConditionsPivotal-lookingRecruiting
TakedaTakeda (TAK)
NCT05816382 · 500 participants (planned) · Start Apr 5, 2023 · Primary completion Feb 28, 2028
Drug: TAK-861 · For: Narcolepsy Type 1
Sites: Birmingham, Alabama; Redwood City, California; Santa Ana, California · 52 sites in all
- A Study of TAK-360 in People With Narcolepsy or Idiopathic HypersomniaPivotal-lookingRecruiting
TakedaTakeda (TAK)
NCT07646678 · 500 participants (planned) · Start Jun 11, 2026 · Primary completion Jun 15, 2031
Drug: TAK-360; Placebo · For: Idiopathic Hypersomnia; Narcolepsy Type 1; Narcolepsy Type 2
Sites: Chula Vista, California; Santa Ana, California; Colorado Springs, Colorado · 33 sites in all
- A Study of TAK-330 to Reverse the Effects of Factor Xa Inhibitors For Adults Needing Urgent SurgeryPivotal-lookingRecruiting
TakedaTakeda (TAK)
NCT05156983 · 440 participants (planned) · Start Aug 24, 2022 · Primary completion Aug 30, 2028
Drug: TAK-330; SOC 4F-PCC · For: Coagulation Disorder
Sites: Arkansas City, Arkansas; Sacramento, California; Englewood, Colorado · 64 sites in all
- A Study of Vedolizumab in Adult Participants With Moderate to Severe Crohn's DiseasePivotal-lookingRecruiting
TakedaTakeda (TAK)
NCT05837897 · 408 participants (planned) · Start Jun 16, 2023 · Primary completion Mar 8, 2030
Drug: Vedolizumab IV; Placebo · For: Crohn's Disease
Sites: Hefei, China; Wuhu, China; Beijing, China · 43 sites in all
- A Study of Vedolizumab With and Without Upadacitinib in Adults With Crohn's DiseasePivotal-lookingRecruiting
TakedaTakeda (TAK)
NCT06227910 · 396 participants (planned) · Start Jan 2, 2025 · Primary completion Jun 8, 2027
Drug: Vedolizumab; Upadacitinib and 1 more · For: Crohn's Disease
Sites: La Jolla, California; Los Angeles, California; Colorado Springs, Colorado · 138 sites in all
- A Study of Mezagitamab in Adults With Kidney Condition Called IgA NephropathyPivotal-lookingRecruiting
TakedaTakeda (TAK)
NCT06963827 · 347 participants (planned) · Start Jul 15, 2025 · Primary completion Sep 7, 2028
Drug: Mezagitamab; Placebo · For: Kidney Disease
Sites: Birmingham, Alabama; Montgomery, Alabama; Surprise, Arizona · 186 sites in all
- A Study to Compare Elritercept to Placebo in Adults With Myelofibrosis and Anemia Who Are Taking RuxolitinibPivotal-lookingRecruiting
TakedaTakeda (TAK)
NCT07623161 · 324 participants (planned) · Start Sep 10, 2026 · Primary completion Dec 7, 2029
Drug: Placebo; Elritercept · For: Myelofibrosis; Anemia
Sites: Gilbert, Arizona; Glendale, California; Whittier, California · 214 sites in all
- A Study to Compare Elritercept With Epoetin Alfa to Treat Anemia in Adults With Lower Risk Myelodysplastic Syndromes (LR-MDS) Who Need Regular Blood TransfusionsPivotal-lookingRecruiting
TakedaTakeda (TAK)
NCT07422480 · 300 participants (planned) · Start May 21, 2026 · Primary completion Apr 30, 2029
Drug: Elritercept; Epoetin Alfa · For: Myelodysplastic Syndrome; Anemia
Sites: Gilbert, Arizona; Duarte, California; Santa Rosa, California · 166 sites in all
Marketed drugs (40)
Newest FDA action first.
- Lialda Mesalamine · 2007
- Pentasa Mesalamine · 1993
- Mimrylo Rusfertide Acetate · 2026
- Gattex Kit Teduglutide · 2012
- Actoplus Met Metformin Hydrochloride, Pioglitazone Hydrochloride · 2005
- Kazano Alogliptin Benzoate, Metformin Hydrochloride · 2013
- Orzeyful Oveporexton · 2026
- Vyvanse Lisdexamfetamine Dimesylate · 2017
- Vyvanse Lisdexamfetamine Dimesylate · 2007
- Adderall Xr 10 Amphetamine Aspartate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate · 2001
- Mydayis Amphetamine Aspartate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate · 2017
- Entyvio Vedolizumab · 2014
- Entyvio Vedolizumab · 2023
- Livtencity Maribavir · 2021
- Iclusig Ponatinib Hydrochloride · 2012
- Motegrity Prucalopride Succinate · 2018
- Fruzaqla Fruquintinib · 2023
- Fosrenol Lanthanum Carbonate · 2004
- Fosrenol Lanthanum Carbonate · 2014
- Vpriv Velaglucerase Alfa · 2010
- Ninlaro Ixazomib Citrate · 2015
- Oseni Alogliptin Benzoate, Pioglitazone Hydrochloride · 2013
- Eohilia Budesonide · 2024
- Entyvio Vedolizumab · 2024
- Firazyr Icatibant Acetate · 2011
- Trintellix Vortioxetine Hydrobromide · 2013
- Prevacid Lansoprazole · 2002
- Prevacid Lansoprazole · 1995
- Nesina Alogliptin Benzoate · 2013
- Dexilant Dexlansoprazole · 2009
- Uloric Febuxostat · 2009
- Carbatrol Carbamazepine · 1997
- Alunbrig Brigatinib · 2017
- Velcade Bortezomib · 2003
- Rozerem Ramelteon · 2005
- Agrylin Anagrelide Hydrochloride · 1997
- Intuniv Guanfacine Hydrochloride · 2009
- Elaprase Idursulfase · 2006
- Actos Pioglitazone Hydrochloride · 1999
- Duetact Glimepiride, Pioglitazone Hydrochloride · 2006
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.